Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Tolcher, A W; Gerson, S L; Denis, L; Geyer, C; Hammond, L A; Patnaik, A; Goetz, A D; Schwartz, G; Edwards, T; Reyderman, L; Statkevich, P; Cutler, D L; Rowinsky, E K

Tolcher, A W; Gerson, S L; Denis, L; Geyer, C; Hammond, L A; Patnaik, A; Goetz, A D; Schwartz, G; Edwards, T; Reyderman, L; Statkevich, P; Cutler, D L; Rowinsky, E K.

Affiliation

Tolcher AW; Institute of Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA. atolcher@saci.org

Br J Cancer ; 88(7): 1004-11, 2003 Apr 07.

Article in En | MEDLINE | ID: mdl-12671695

Subject(s)

Antineoplastic Agents, Alkylating/administration & dosage; Dacarbazine/analogs & derivatives; Dacarbazine/administration & dosage; Enzyme Inhibitors/pharmacology; O(6)-Methylguanine-DNA Methyltransferase/antagonists & inhibitors; Dacarbazine/pharmacology; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukocytes, Mononuclear/enzymology; Temozolomide

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Agents, Alkylating / O(6)-Methylguanine-DNA Methyltransferase / Dacarbazine / Enzyme Inhibitors Limits: Humans Language: En Journal: Br J Cancer Year: 2003 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google